Nucana shares surge 10.02% after-hours as NUC-7738 program advances with FDA strategy discussions and Phase 1/2 data expected in 2026.

Nucana surged 10.02% in after-hours trading following news of key clinical advancements in its NUC-7738 program. The biotech firm announced plans to advance combination trials with pembrolizumab for PD-1-resistant patients, with phase 1/2 data expected in 2026. Upcoming FDA strategy discussions were highlighted as critical milestones, signaling progress toward late-stage development. While technical analysis from earlier in the day noted bearish momentum, the after-hours rally directly aligned with the positive clinical pipeline updates, which position Nucana to address unmet needs in oncology resistance. Financial stability through 2029 further reinforced investor confidence in the company’s long-term research capabilities.